Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
Clinical trial NCT00351858 · TERMINATED
Trial details
- NCT number
- NCT00351858
- Sponsor
- Neovii Biotech
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-07-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.